Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 May;37(5):433–439. doi: 10.1111/j.1365-2125.1994.tb05710.x

Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.

N H Holford 1, T W Guentert 1, J Dingemanse 1, L Banken 1
PMCID: PMC1364898  PMID: 7519866

Abstract

1. Single oral doses of 300, 450 and 600 mg moclobemide, a monoamine oxidase type A inhibitor, were administered in a cross-over design to eight healthy male volunteers. Plasma concentrations of the parent drug and of two monoamine metabolites (3,4-dihydroxyphenylglycol DHPG from noradrenaline; 5-hydroxy-indoleacetic acid 5HIAA from serotonin) were measured over time. 2. A physiological pharmacokinetic-pharmacodynamic model was used to describe MAO-A inhibition as reflected in the alterations of monoamine metabolites. Population values for the model parameters were obtained by a two-stage method allowing for repeated dosing per subject. 3. Even at the lowest dose an effect of moclobemide on plasma DHPG and 5HIAA concentrations was detectable in most subjects for up to 24 h. In contrast to DHPG, 5HIAA formation was only partially suppressed by moclobemide (maximum fractional extent of enzyme inhibition Imax: 0.57, CV 26%) suggesting the existence of 5HIAA formation pathways independent of those inhibitable by moclobemide. 4. Plasma moclobemide concentrations associated with 50% of maximum enzyme inhibition (IC50) were in the range of 100 (IC50,5HIAA at 300 mg) to 400 micrograms l-1 (IC50,DHPG at 600 mg).

Full text

PDF
433

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berlin I., Zimmer R., Thiede H. M., Payan C., Hergueta T., Robin L., Puech A. J. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805–816. doi: 10.1111/j.1365-2125.1990.tb05445.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cesura A. M., Kettler R., Imhof R., Da Prada M. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology (Berl) 1992;106 (Suppl):S15–S16. doi: 10.1007/BF02246226. [DOI] [PubMed] [Google Scholar]
  3. Dingemanse J., Korn A., Pfefen J. P., Güntert T. W. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacology (Berl) 1992;106 (Suppl):S46–S48. doi: 10.1007/BF02246235. [DOI] [PubMed] [Google Scholar]
  4. Eisenhofer G., Goldstein D. S., Kopin I. J. Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal re-uptake in the sympathetic nervous system in vivo. Clin Sci (Lond) 1989 Feb;76(2):171–182. doi: 10.1042/cs0760171. [DOI] [PubMed] [Google Scholar]
  5. Fitton A., Faulds D., Goa K. L. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs. 1992 Apr;43(4):561–596. doi: 10.2165/00003495-199243040-00009. [DOI] [PubMed] [Google Scholar]
  6. Geschke R., Körner J., Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. J Chromatogr. 1987 Sep 4;420(1):111–120. doi: 10.1016/0378-4347(87)80160-3. [DOI] [PubMed] [Google Scholar]
  7. Guentert T. W., Tucker G., Korn A., Pfefen J. P., Haefelfinger P., Schoerlin M. P. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatr Scand Suppl. 1990;360:91–93. doi: 10.1111/j.1600-0447.1990.tb05345.x. [DOI] [PubMed] [Google Scholar]
  8. Halbrügge T., Wölfel R., Graefe K. H. Plasma 3,4-dihydroxyphenylglycol as a tool to assess the role of neuronal uptake in the anaesthetized rabbit. Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6 Pt 2):726–732. doi: 10.1007/BF00169681. [DOI] [PubMed] [Google Scholar]
  9. Jauch R., Griesser E., Oesterhelt G., Arnold W., Meister W., Ziegler W. H., Guentert T. W. Biotransformation of moclobemide in humans. Acta Psychiatr Scand Suppl. 1990;360:87–90. doi: 10.1111/j.1600-0447.1990.tb05344.x. [DOI] [PubMed] [Google Scholar]
  10. Koulu M., Scheinin M., Kaarttinen A., Kallio J., Pyykkö K., Vuorinen J., Zimmer R. H. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol. 1989 Feb;27(2):243–255. doi: 10.1111/j.1365-2125.1989.tb05357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Murphy D. L., Sims K. B., Karoum F., Garrick N. A., de la Chapelle A., Sankila E. M., Norio R., Breakefield X. O. Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neural Transm Gen Sect. 1991;83(1-2):1–12. doi: 10.1007/BF01244447. [DOI] [PubMed] [Google Scholar]
  12. Murphy D. L., Sims K. B., Karoum F., de la Chapelle A., Norio R., Sankila E. M., Breakefield X. O. Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neurochem. 1990 Jan;54(1):242–247. doi: 10.1111/j.1471-4159.1990.tb13307.x. [DOI] [PubMed] [Google Scholar]
  13. Raaflaub J., Haefelfinger P., Trautmann K. H. Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. Arzneimittelforschung. 1984;34(1):80–82. [PubMed] [Google Scholar]
  14. Racine-Poon A. A Bayesian approach to nonlinear random effects models. Biometrics. 1985 Dec;41(4):1015–1023. [PubMed] [Google Scholar]
  15. Scheinin M., Karhuvaara S., Ojala-Karlsson P., Kallio A., Koulu M. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci. 1991;49(1):75–84. doi: 10.1016/0024-3205(91)90581-u. [DOI] [PubMed] [Google Scholar]
  16. Schoerlin M. P., Mayersohn M., Korn A., Eggers H. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther. 1987 Oct;42(4):395–404. doi: 10.1038/clpt.1987.169. [DOI] [PubMed] [Google Scholar]
  17. Sheiner L. B., Beal S. L. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981 Oct;9(5):635–651. doi: 10.1007/BF01061030. [DOI] [PubMed] [Google Scholar]
  18. Stabl M., Biziére K., Schmid-Burgk W., Amrein R. Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm Suppl. 1989;28:77–89. [PubMed] [Google Scholar]
  19. Waldmeier P. C. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J Neural Transm Suppl. 1987;23:55–72. doi: 10.1007/978-3-7091-8901-6_4. [DOI] [PubMed] [Google Scholar]
  20. Weyler W., Hsu Y. P., Breakefield X. O. Biochemistry and genetics of monoamine oxidase. Pharmacol Ther. 1990;47(3):391–417. doi: 10.1016/0163-7258(90)90064-9. [DOI] [PubMed] [Google Scholar]
  21. Wiesel F. A., Raaflaub J., Kettler R. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol. 1985;28(1):89–95. doi: 10.1007/BF00635714. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES